Clinical trials: Salivary Immunity
- Condition Salivary Immunity
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Immune Function, Immunity
Effects of TM02® Supplementation on Immune Function in Children
This randomized, double-blind, placebo-controlled clinical study evaluated the effects of 12 weeks of TM02® supplementation on immune-related outcomes in generally healthy children aged 2 to 12 years.
- Trial name
- NCT07853573
- Testing
- TM02®
- Where
- Malaysia
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Ligno Biotech Sdn. Bhd.
Measles, Measles-Mumps-Rubella+Chickenpox Vaccine
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Administered as Intramuscular Injection to Healthy Children 15 Months to 6 Years of Age
This study is evaluating the immunogenicity and safety of intramuscular administration of the investigational MMRVNS vaccine compared to intramuscular administration of the MMRV (Merck's measles, mumps, rubella and varicella)…
- Trial name
- NCT07406360
- Testing
- MMRVNS, MMRV
- Where
- 17 sites in United States
- Volunteers
- 1,209 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles; Mumps; Rubella; Chickenpox, Measles
A Study on the Immune Response and Safety of a Combined Measles, Mumps, Rubella, Chickenpox Vaccine Compared to a Marketed Combined Vaccine, Given to Healthy Children 4 to 6 Years of Age
The main purpose of this study is to assess immune response and safety of various potencies of a measles, mumps, rubella, and varicella (MMRVNS) vaccines given to healthy children of 4 to 6 years of age.
- Trial name
- NCT05630846
- Testing
- Investigational MMRV(H)NS vaccine, Investigational MM(H)RVNS vaccine, Investigational M(L)M(L)R(L)V(L)NS vaccine
- Where
- 47 sites in United States, Colombia and 3 more
- Volunteers
- 801 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Measles, Mumps
A Study on the Immune Response and Safety of an Investigational Combined Measles, Mumps, Rubella and Varicella Vaccine, When Given to Healthy Children 4 to 6 Years of Age
The purpose of this study is to evaluate how consistently 3 different manufacturing lots of the GSK's investigational measles, mumps, rubella, and varicella (MMRVNS) vaccine will produce an immune response.
- Conditions
- Measles, Mumps, Rubella, Varicella (Chickenpox)
- Trial name
- MMRVNS 20-002 (NCT07742644)
- Testing
- MMRVNS vaccine, MMRV vaccine, DTaP-IPV vaccine
- Where
- 62 sites in United States, Argentina and 4 more
- Volunteers
- 1,860 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Meningococcal Infections
Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers
Safety immune response of Novartis MenACWY-CRM conjugate vaccine when given to healthy toddlers
- Trial name
- NCT00626327
- Testing
- MenACWY-CRM + MMRV, MMRV, MenACWY-CRM
- Where
- 90 sites in United States
- Volunteers
- 1,630 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines